Almohsen Faez, Al-Rubaie Haithem A, Habib Manal A, Nasr Sherif A, Perni Rajendra, Al-Quraishi Lubab
College of Medicine, University of Baghdad, Baghdad, Iraq.
siParadigm Diagnostic Informatics, New Jersey, NJ, USA.
J Blood Med. 2022 Feb 18;13:83-92. doi: 10.2147/JBM.S347397. eCollection 2022.
Acute myeloid leukemia (AML) results from sequential genetic alterations in a normal hematopoietic stem cell or its progenitors giving rise to an autonomous clone that dominates the bone marrow leading to marrow failure. MicroRNAs are short non-coding nucleic acid sequences that regulate post-transcriptional gene expression by base-pairing with their target mRNAs. MiRNAs can be secreted into extracellular fluids and carried to target cells by vesicles or bound to proteins. Intracellular and circulating miRNAs are believed to be useful markers in the diagnosis, prognosis, and treatment of various cancers. Practically, circulating miRNAs are more stable at room temperatures and extreme conditions.
This study aimed to compare the expression of miR-126-3p and miR-423-5p in patients and normal subjects and correlate their expression with response to induction therapy and with their 2-year overall survival rate.
Circulating miR-126-3p and miR-423-5p was measured in the plasma of 43 adult AML patients and 35 age- and sex-matched controls by quantitative reverse transcriptase PCR. The fold change in differential expression for each gene was calculated using the comparative cycle threshold method.
There was an increase in the expression of the studied miRNAs in patients compared to the control group. The average expression fold change of miR-126-3p was 3.02 (= 0.010). The average expression fold change of miR-423-5p was 4.09 (= 0.003). No significant correlation was found between the expression of miR-126-3p and miR-423-5p in the studied AML patients (r = 0.094, p = 0.22). Furthermore, no relationship was found between the expression of the studied miRNAs and response to induction therapy or the 2-year survival rate.
Although further studies are needed, our findings highlight the studied circulating miRNAs as possible diagnostic markers for AML.
急性髓系白血病（AML）源于正常造血干细胞或其祖细胞的一系列基因改变，产生一个自主克隆，该克隆主导骨髓，导致骨髓衰竭。微小RNA（miRNA）是短的非编码核酸序列，通过与其靶mRNA碱基配对来调节转录后基因表达。miRNA可分泌到细胞外液中，并通过囊泡携带至靶细胞或与蛋白质结合。细胞内和循环中的miRNA被认为是各种癌症诊断、预后和治疗的有用标志物。实际上，循环miRNA在室温及极端条件下更稳定。
本研究旨在比较miR-126-3p和miR-423-5p在患者和正常受试者中的表达，并将其表达与诱导治疗反应及2年总生存率相关联。
采用定量逆转录聚合酶链反应检测43例成年AML患者和35例年龄及性别匹配对照者血浆中循环miR-126-3p和miR-423-5p。使用比较循环阈值法计算每个基因差异表达的倍数变化。
与对照组相比，患者中所研究miRNA的表达增加。miR-126-3p的平均表达倍数变化为3.02（P = 0.010）。miR-423-5p的平均表达倍数变化为4.09（P = 0.003）。在所研究的AML患者中，miR-126-3p和miR-423-5p的表达之间未发现显著相关性（r = 0.094，P = 0.22）。此外，所研究miRNA的表达与诱导治疗反应或2年生存率之间未发现相关性。
尽管需要进一步研究，但我们的发现突出了所研究的循环miRNA作为AML潜在诊断标志物的可能性。
